AgeX Therapeutics, a subsidiary of BioTime (NYSEMKT:BTX) has closed a $5M equity financing, through the sale of 2M AgeX common shares to Juvenescence Ltd. Following the sale, BioTime owns ~80.6% of AgeX’s outstanding shares and Juvenescence and its principals owns ~7%.
Shares of BTX up 3% premarket.
Previously: BioTime files for distribution of AgeX shares (June 8)
Subscribe for full text news in your inbox